Positive Safety Data from First Cohort of Phase I
Clinical Trial Evaluating Healthy Subjects
Intravenously Dosed with RECCE®327
Highlights:
•9 subjects in cohort one intravenously dosed with RECCE®327 at 50mg meet sall
end-points, indicating to be safe and well tolerated
•Independent Safety Committee clears second study cohort to be dosed at 150mg
-a three fold increase in dose per approved protocol
•Second cohort recruited; healthy subjects to be dosed 7January 2022
Ann: Positive Safety Data from Phase 1 Clinical Trial, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.005(1.69%) |
Mkt cap ! $86.51M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.5¢ | $29.69K | 102.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6825 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 6555 | 2 |
View Market Depth
| Last trade - 12.29pm 24/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |